Full Press Release Details
Mereo BioPharma Group plc
City, Calif., October 12, 2020 Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), Mereo or the Company , a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that
on October 09, 2020, Charles Sermon, General Counsel at Mereo, purchased 18,405 American Depositary Shares (ADSs) at a price of USD 2.41 per ADS.
below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
| 1 | Details of the person discharging managerial responsibilities | |||||||||
| a) | Name | Charles Sermon | ||||||||
| 2 | Reason for the notification | |||||||||
| a) | Position/status | General Counsel | ||||||||
| b) | Initial notification/Amendment | Initial notification | ||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||
| a) | Name | Mereo BioPharma Group plc | ||||||||
| b) | LEI | 213800U8JQHIJOS5AS09 | ||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
| a) | Description of the financial instrument, type of instrument and identification code | AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF 0.003 EACH | ||||||||
| b) | Nature of the transaction | PURCHASE | ||||||||
| c) | Price(s) and volume(s) | |||||||||
| Price(s) | Volume(s) | |||||||||
| USD 2.41 | 18,405 | |||||||||
| d) | Aggregated information: volume, Price | |||||||||
| e) | Date of the transaction | 2020-10-09 | ||||||||
| f) | Place of the transaction | XNMS (Nasdaq Global Market) |